AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20150300 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of mild GDM during pregnancy
Number of subjects: 199
Study 20150300 — intervention group
Group type: COMPARATOR
Intervention: Routine care control group
Number of subjects: 199
Study 16769748 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomifene citrate plus metformin
Number of subjects: 228
Study 16769748 — intervention group
Group type: COMPARATOR
Intervention: Clomifene citrate plus placebo
Number of subjects: 228
Study 14992910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass established through the femoral artery and vein before sternal reentry (Group 1, n = 100)
Number of subjects: 200
Study 14992910 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary bypass performed after sternal reentry (Group 2, n = 100)
Number of subjects: 200
Study 11547841 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplementation (50 g of milk powder containing 800 mg of calcium per day)
Number of subjects: 200
Study 11547841 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 9211762 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC)
Number of subjects: 20
Study 9211762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7584268 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming effects through category fluency task
Number of subjects: 0
Study 7584268 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical category instances as targets
Number of subjects: 0
Study 7584268 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical category instances as targets
Number of subjects: 0
Study 3319639 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 6
Study 3319639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31917621 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombomodulin alfa (380 U/kg/d for 14 days by intravenous drip infusion)
Number of subjects: 82
Study 31917621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 31917621 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombomodulin alfa
Number of subjects: 82
Study 30503879 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 1463
Study 29282142 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME complex intervention (recruitment co-ordinator, bespoke stroke audit data exports, follow-up review after 6 months)
Number of subjects: 72
Study 29282142 — intervention group
Group type: COMPARATOR
Intervention: Control (before allocation to the PRIME complex intervention)
Number of subjects: 72
Study 25722979 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 156
Study 25722979 — intervention group
Group type: COMPARATOR
Intervention: Nonclipping
Number of subjects: 156
Study 24457205 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss programme delivered by community coaching staff in 12 sessions held every week
Number of subjects: 747
Study 24457205 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 747
Study 22375955 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion tub bathing
Number of subjects: 100
Study 22375955 — intervention group
Group type: COMPARATOR
Intervention: Sponge bathing
Number of subjects: 100
Study 19222416 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided coeliac plexus block (EUS-CPB)
Number of subjects: 56
Study 19222416 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous fluoroscopy guided coeliac plexus block (PCFG-CPB)
Number of subjects: 56
Study 17692438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) route with 3, 6, or 9 microg of vaccine
Number of subjects: 0
Study 17692438 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) route with 15 microg of vaccine
Number of subjects: 0
Study 17692438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) route
Number of subjects: 0
Study 17692438 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) route
Number of subjects: 0
Study 15640721 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0
Study 15640721 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic alternatives
Number of subjects: 0
Study 12373440 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg alcohol
Number of subjects: 12
Study 12373440 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.3% THC
Number of subjects: 12
Study 12373440 — intervention group
Group type: COMPARATOR
Intervention: 0.25 g/kg alcohol
Number of subjects: 12
Study 12373440 — intervention group
Group type: COMPARATOR
Intervention: 0 g/kg alcohol
Number of subjects: 12
Study 12373440 — intervention group
Group type: COMPARATOR
Intervention: 0% THC
Number of subjects: 12
Study 12373440 — intervention group
Group type: COMPARATOR
Intervention: 1.75% THC
Number of subjects: 12
Study 10425052 — intervention group
Group type: EXPERIMENTAL
Intervention: Pap tests reported as CIN I
Number of subjects: 449
Study 10425052 — intervention group
Group type: COMPARATOR
Intervention: First review
Number of subjects: 449
Study 10425052 — intervention group
Group type: COMPARATOR
Intervention: Second review
Number of subjects: 449
Study 10425052 — intervention group
Group type: EXPERIMENTAL
Intervention: Final classification
Number of subjects: 449
Study 10425052 — intervention group
Group type: EXPERIMENTAL
Intervention: Undercalls
Number of subjects: 449
Study 10425052 — intervention group
Group type: EXPERIMENTAL
Intervention: Overcalls
Number of subjects: 449
Study 8525125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (FIO2 = 0.14)
Number of subjects: 6
Study 8525125 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (room air)
Number of subjects: 6
Study 8525125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO2 = 0.70)
Number of subjects: 6
Study 2255416 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 46
Study 2255416 — intervention group
Group type: COMPARATOR
Intervention: Control (no Thymopentin)
Number of subjects: 46
Study 6997212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 17
Study 6997212 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 17
Study 31134488 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab and/or lapatinib for 1 year
Number of subjects: 6273
Study 31134488 — intervention group
Group type: COMPARATOR
Intervention: Control group (HR-negative tumors)
Number of subjects: 6273
Study 28035589 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin 100 mg loading dose followed by 50 mg maintenance dose for patients with total body weight of ≤80 kg
Number of subjects: 9
Study 28035589 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin 70 mg maintenance dose for patients with total body weight of >80 kg
Number of subjects: 9
Study 28035589 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin CRRT clearance (CL) for CVVH
Number of subjects: 9
Study 28035589 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin CRRT clearance (CL) for CVVHDF
Number of subjects: 9
Study 28035589 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin pharmacokinetic parameters
Number of subjects: 9
Study 25297372 — intervention group
Group type: EXPERIMENTAL
Intervention: In-house biochemistry analysers
Number of subjects: 94
Study 25297372 — intervention group
Group type: COMPARATOR
Intervention: Commercial laboratory analyser
Number of subjects: 94
Study 23375819 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 3 g/d
Number of subjects: 32
Study 23375819 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (0.5‐1 g/m²)
Number of subjects: 32
Study 21516030 — intervention group
Group type: EXPERIMENTAL
Intervention: tesamorelin (2 mg subcutaneously daily for 26 weeks)
Number of subjects: 410
Study 21516030 — intervention group
Group type: COMPARATOR
Intervention: placebo (subcutaneously daily for 26 weeks)
Number of subjects: 410
Study 21516030 — intervention group
Group type: EXPERIMENTAL
Intervention: tesamorelin
Number of subjects: 410
Study 19050966 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation with additional Prolene suture placed by the surgeon on one side
Number of subjects: 122
Study 17279300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1 g/day and tinidazole 15 mg/kg/day for 4 weeks
Number of subjects: 16
Study 17279300 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine (4 g/day oral, 8 g/day enema, or 1 g/day suppository)
Number of subjects: 16
Study 15484217 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose suramin
Number of subjects: 385
Study 15484217 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose suramin
Number of subjects: 385
Study 15484217 — intervention group
Group type: COMPARATOR
Intervention: High-dose suramin
Number of subjects: 385
Study 15484217 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups post-treatment
Number of subjects: 385
Study 11939497 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 102
Study 11939497 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 102
Study 9879787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 20
Study 9879787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8028755 — intervention group
Group type: EXPERIMENTAL
Intervention: carbocalcitonin + arginine-lysine-lactose combination
Number of subjects: 40
Study 8028755 — intervention group
Group type: COMPARATOR
Intervention: carbocalcitonin alone (40 UMRC day i.m. on alternative days)
Number of subjects: 40
Study 2653110 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone-undecanoate 120 mg per os for 100 days
Number of subjects: 60
Study 2653110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 887645 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 IU daily of synthetic oxytocin
Number of subjects: 29
Study 887645 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU daily of synthetic oxytocin
Number of subjects: 29
Study 887645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31720836 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthokeratology lenses
Number of subjects: 50
Study 31561192 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time medication monitoring pill bottle linked to an HIV self-management app
Number of subjects: 38
Study 28327114 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral laminotomy with crossover
Number of subjects: 465
Study 28327114 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral laminotomy
Number of subjects: 465
Study 28327114 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinous process osteotomy
Number of subjects: 465
Study 28327114 — intervention group
Group type: EXPERIMENTAL
Intervention: All techniques
Number of subjects: 465
Study 1445478 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg q.d.
Number of subjects: 203
Study 1445478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg t.i.d.
Number of subjects: 203
Study 1445478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 22048237 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (100 mg orally twice daily in 28-day cycles)
Number of subjects: 200
Study 22048237 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (200 mg/m2/day for 5 days, then 23 days off-treatment)
Number of subjects: 200
Study 22048237 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (in patients with BRAF mutations)
Number of subjects: 200
Study 22048237 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (in patients with BRAF mutations)
Number of subjects: 200
Study 22048237 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 200
Study 22048237 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide
Number of subjects: 200
Study 20413076 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 2067
Study 20413076 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A virus vaccine (control)
Number of subjects: 2067
Study 18396374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 0
Study 18396374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 0
Study 18396374 — intervention group
Group type: COMPARATOR
Intervention: Experimental inflammation (UVB)
Number of subjects: 0
Study 18396374 — intervention group
Group type: COMPARATOR
Intervention: Noxious heat
Number of subjects: 0
Study 16433603 — intervention group
Group type: EXPERIMENTAL
Intervention: Biogel Indicator Glove System (indicator gloves)
Number of subjects: 25
Study 16433603 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex indicator gloves
Number of subjects: 25
Study 16433603 — intervention group
Group type: COMPARATOR
Intervention: Worst-performing latex gloves
Number of subjects: 25
Study 16433603 — intervention group
Group type: COMPARATOR
Intervention: Worst-performing synthetic gloves
Number of subjects: 25
Study 16433603 — intervention group
Group type: COMPARATOR
Intervention: Non-indicator gloves
Number of subjects: 25
Study 12629088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 451
Study 12629088 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 451
Study 10597132 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral vaporization of the prostate (TUVP)
Number of subjects: 78
Study 10597132 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 78
Study 8743100 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage at -20 degrees C for 6 months
Number of subjects: 85
Study 8743100 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage at -20 degrees C for up to 46 months
Number of subjects: 85
Study 1836986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg/day
Number of subjects: 235
Study 1836986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5.0 mg/day
Number of subjects: 235
Study 1836986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 10.0 mg/day
Number of subjects: 235
Study 1836986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 6297841 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal, 50 gm
Number of subjects: 6
Study 6297841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 6
Study 6297841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonium chloride
Number of subjects: 6
Study 6297841 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinization of urine
Number of subjects: 6
Study 6297841 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidification of urine
Number of subjects: 6
Study 30682843 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate High Fat (LCHF) diet
Number of subjects: 0
Study 30682843 — intervention group
Group type: COMPARATOR
Intervention: High Carbohydrate (HCHO) diet
Number of subjects: 0
Study 30682843 — intervention group
Group type: COMPARATOR
Intervention: Periodised Carbohydrate (PCHO) diet
Number of subjects: 0
Study 30962603 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized information treatments targeting parents' misbeliefs about their children's absences
Number of subjects: 28080
Study 30962603 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional information)
Number of subjects: 28080
Study 27089808 — intervention group
Group type: EXPERIMENTAL
Intervention: LEXICAL (representing the output of the lexical phonology)
Number of subjects: 97
Study 27089808 — intervention group
Group type: EXPERIMENTAL
Intervention: DEEP (an experimental orthography representing the input of the lexical phonology)
Number of subjects: 97
Study 27089808 — intervention group
Group type: EXPERIMENTAL
Intervention: PHONEMIC (representing a level between the output of the lexical phonology and the output of the post‐lexical phonology)
Number of subjects: 97
Study 27089808 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 23592025 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (TNA) 10 mg/kg administered intravenously 20 min before tourniquet deflation and repeated 3 h after surgery for unilateral TKA; an additional dose of TNA 10 mg/kg before tourniquet deflation for the second TKA in bilateral TKA patients.
Number of subjects: 326
Study 22275464 — intervention group
Group type: EXPERIMENTAL
Intervention: GaitMaster gait rehabilitation
Number of subjects: 12
Study 22275464 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention phase)
Number of subjects: 12
Study 19184351 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse (CHX)
Number of subjects: 50
Study 19184351 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 50
Study 17216337 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua‐E (water-soluble vitamin E formulation)
Number of subjects: 8
Study 17216337 — intervention group
Group type: COMPARATOR
Intervention: Oil‐based softgels (control)
Number of subjects: 8
Study 16452103 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham device (validated sham acupuncture needle)
Number of subjects: 270
Study 16452103 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 270
Study 16452103 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham device
Number of subjects: 270
Study 14675055 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg orally for 10 days during LBNP
Number of subjects: 20
Study 14675055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10797163 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up home visits by a physician (INT1-HVP)
Number of subjects: 155
Study 10797163 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions by a physiotherapist in their home (INT2-PI)
Number of subjects: 155
Study 10797163 — intervention group
Group type: COMPARATOR
Intervention: Standard aftercare (controls)
Number of subjects: 155
Study 8970145 — intervention group
Group type: EXPERIMENTAL
Intervention: 120% VO2peak
Number of subjects: 10
Study 8970145 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 W.kg‐1
Number of subjects: 10
Study 8970145 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% VO2peak + 10% PAS
Number of subjects: 10
Study 8970145 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% VO2peak + 20% MAS
Number of subjects: 10
Study 1450093 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 8
Study 1450093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3912093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PGE1 (15 micrograms/h for 72 h)
Number of subjects: 16
Study 3912093 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 16
Study 31676660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Group Therapy (CRGT) - combining mindfulness-based stress reduction with brain training activities
Number of subjects: 0
Study 31676660 — intervention group
Group type: COMPARATOR
Intervention: Mutual Aid Group Therapy (active control)
Number of subjects: 0
Study 31676660 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (CRGT and Mutual Aid Group Therapy)
Number of subjects: 0
Study 26797106 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g and tramadol 1 mg/kg (group 1T)
Number of subjects: 94
Study 26797106 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1 g and tramadol 1.5 mg/kg (group 1.5T)
Number of subjects: 94
Study 25844849 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in maternal education
Number of subjects: 1624
Study 25844849 — intervention group
Group type: COMPARATOR
Intervention: Control group (mothers did not increase education)
Number of subjects: 1624
Study 23911336 — intervention group
Group type: EXPERIMENTAL
Intervention: Third tertile of dairy intake (≥2.2 servings/day)
Number of subjects: 1456
Study 23911336 — intervention group
Group type: COMPARATOR
Intervention: First tertile of dairy intake (≤1.5 servings/day)
Number of subjects: 1456
Study 21352613 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning discussions with an independent mediator (maximum three sessions)
Number of subjects: 77
Study 21352613 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participation
Number of subjects: 77
Study 19702638 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based environmental and educational intervention promoting water consumption
Number of subjects: 17
Study 17904748 — intervention group
Group type: EXPERIMENTAL
Intervention: ReCell system
Number of subjects: 82
Study 17904748 — intervention group
Group type: COMPARATOR
Intervention: Classic skin grafting
Number of subjects: 82
Study 15515192 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (UK) instillation (100,000 IU in 150 ml normal saline daily)
Number of subjects: 43
Study 15515192 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-tuberculous agents only)
Number of subjects: 43
Study 11584199 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete autonomic nerve‐preserving surgery without lateral node dissection (D1)
Number of subjects: 51
Study 11584199 — intervention group
Group type: COMPARATOR
Intervention: Surgery with dissection of the lateral lymph nodes including autonomic nerves (D2) followed by oral administration of carmofur for one year
Number of subjects: 51
Study 9040712 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 104
Study 9040712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 8200466 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon catheter with extra-amniotic saline infusion (BCEAS)
Number of subjects: 109
Study 8200466 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 (PGE2) vaginal pessaries
Number of subjects: 109
Study 3316312 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (ALP)
Number of subjects: 79